2nd Quarter - Report

NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) for NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)

Firm
Client
Income
—
Expenses
—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

American Health Care Act; H.R.1628 Better Care Reconciliation Act Children's Health Insurance Program Reauthorization Medical Nutrition Equity Act; H.R.2587, S.1194 FDA Reauthorization Act; H.R.2430 FDA Office of Patient Affairs Enhanced Clinical Trial Design Act; S.1048 Orphan Drug Tax Credit Right to Try Act; H.R.878, S.204 OPEN Act; H.R.1223 FDA Funding NIH Funding RACE for Children Act; H.R.1231 Zika Appropriations Newborn Screening Appropriations

LobbyistCovered position, as disclosed
PAUL MELMEYER —
MARTHA L RINKER Vice President of Public Policy

Contacted: Social Security Administration (SSA); HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 2587 (115th), H.R. 1628 (115th), H.R. 2430 (115th), H.R. 1223 (115th), H.R. 1231 (115th), S. 1048 (115th), H.R. 878 (115th), S. 204 (115th), S. 1194 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.